BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesday.
The company posted quarterly earnings of 14 cents per share which beat the analyst consensus estimate of 5 cents per share. The company reported quarterly sales of $156.413 million which beat the analyst consensus estimate of $151.123 million.
BioCryst Pharma affirmed FY2026 sales guidance of $635.000 million-$660.000 million.
“We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline,” said Charlie Gayer, President and Chief Executive Officer of BioCryst. “ORLADEYO continues to grow because its differentiated oral profile and high level of attack control meet the needs of an increasing number of people living with hereditary angioedema. At the same time, we remain on track with enrollment in our navenibart and BCX17725 pipeline programs. We are also pleased to partner again with Neopharmed Gentili for European rights to navenibart. This progress underscores our strategy to focus on rare diseases where we have deep expertise, execute efficiently, and allocate capital thoughtfully to drive sustainable value for patients and shareholders.”
BioCryst Pharma shares fell 1% to trade at $8.74 on Thursday.
These analysts made changes to their price targets on BioCryst Pharma following earnings announcement.
- Wedbush analyst Laura Chico maintained BioCryst Pharma with an Outperform rating and lowered the price target from $22 to $21.
- Citizens analyst Jonathan Wolleben maintained the stock with a Market Outperform and raised the price target from $25 to $28.
Considering buying BCRX stock? Here’s what analysts think:
Photo via Shutterstock